Emicizumab prophylaxis reduces bleeds in PwHAwI | ISTH

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Emicizumab prophylaxis was safe and reduced bleeds in pediatric patients with hemophilia A and Inhibitors (PwHAwI). 

Why this matters

  • Emicizumab may reduce the treatment/disease burden for pediatric PwHAwI. 

Study design

  • HAVEN 2 is a single-arm, multicenter, open-la...